Acute leukemias in children with Down syndrome

Area of Science:

• Pediatric Oncology
• Genetics
• Hematology

Background:

• Children with Down syndrome (DS) exhibit a significantly elevated risk for both acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).
• Leukemias in DS patients present distinct clinical characteristics and underlying biological mechanisms compared to non-DS children.
• Myeloid leukemia in DS is often preceded by a preleukemic clone, known as transient leukemia or transient myeloproliferative disorder (TMD).

Purpose of the Study:

• To explore the unique biological pathways and genetic factors contributing to leukemogenesis in children with Down syndrome.
• To investigate the transition from transient myeloproliferative disorder to myeloid leukemia in DS patients.
• To utilize this transition as a model for understanding stepwise cancer development and the role of aneuploidy-mediated gene dosage effects.

Main Methods:

• Comparative analysis of leukemia characteristics in DS versus non-DS pediatric populations.
• Longitudinal monitoring of preleukemic clones (TMD) in children with Down syndrome.
• Genetic and molecular profiling to identify key alterations in the stepwise progression to myeloid leukemia.

Main Results:

• A subset of children with DS and TMD (approximately 20%) subsequently develop myeloid leukemia.
• The preleukemic clone in DS can spontaneously resolve or necessitate treatment for severe symptoms.
• This progression provides a unique in vivo model for studying the sequential acquisition of genetic events in leukemia.

Conclusions:

• The transition from TMD to AML in children with Down syndrome is a critical window for understanding leukemia initiation and progression.
• Aneuploidy and gene dosage effects play a crucial role in the development of leukemia in this population.
• Further research into this model can inform targeted therapeutic strategies for pediatric leukemia in Down syndrome.